Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

CV Sciences (CVSI) EBITDA (2016 - 2025)

CV Sciences' EBITDA history spans 14 years, with the latest figure at $196000.0 for Q4 2025.

  • On a quarterly basis, EBITDA rose 130.34% to $196000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$199000.0, a 90.91% increase, with the full-year FY2025 number at -$199000.0, up 90.91% from a year prior.
  • EBITDA hit $196000.0 in Q4 2025 for CV Sciences, up from -$275000.0 in the prior quarter.
  • Over the last five years, EBITDA for CVSI hit a ceiling of $5.8 million in Q1 2023 and a floor of -$8.8 million in Q4 2021.
  • Historically, EBITDA has averaged -$1.1 million across 5 years, with a median of -$633000.0 in 2024.
  • The widest YoY moves for EBITDA: up 480.33% in 2023, down 220.46% in 2023.
  • Tracing CVSI's EBITDA over 5 years: stood at -$8.8 million in 2021, then skyrocketed by 133.78% to $3.0 million in 2022, then plummeted by 220.46% to -$3.6 million in 2023, then surged by 82.05% to -$646000.0 in 2024, then soared by 130.34% to $196000.0 in 2025.
  • Business Quant data shows EBITDA for CVSI at $196000.0 in Q4 2025, -$275000.0 in Q3 2025, and -$131000.0 in Q2 2025.